EichorEICHOR
Study identifier: NCT05623189 Synced from ClinicalTrials.gov · August 09, 2026
● Study status: CompletedCENTRICITY

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

Condition: Nonalcoholic Steatohepatitis (NASH) · Type 2 Diabetes  ·  Sponsor: HighTide Biopharma Pty Ltd

PhasePhase 2
Planned participants218
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNoCheck eligibility criteria ↓
Where45 locations · 3 countries
For sponsors, CROs & site teams
Professional view of this study — listed sites, countries and recruiting context from the public registry. Everything below is written for patients and caregivers.Open the site landscape →

About this study

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Key Inclusion criteria: * Clinical diagnosis of non-alcoholic steatohepatitis (NASH) upon central read of a liver biopsy obtained no more than 6 months before Day 0. * Histologic evidence of fibrosis stage 2 or stage 3 as defined by the non-alcoholic steatohepatitis (NASH) clinical research network (CRN) scoring of fibrosis. * Clinically documented diagnosis of type 2 diabetes mellitus for at least 6 months prior to screening or prediabetes at screening. * BMI \>25 kilograms/meters squared (\>23 kilograms/meters squared if Asian). Key Exclusion criteria: * Fibrosis stage 4. * History of alcohol or substance abuse or dependence. * Liver disease unrelated to non-alcoholic steatohepatitis. * History of significant cardiovascular disease. * History of type 1 diabetes. * Inability or unwillingness to undergo 2 planned liver biopsies OR 1 planned biopsy if historical liver biopsy was used to confirm eligibility at entry.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (45)

The Institute for Liver Health (Arizona Liver Health)Chandler, Arizona, United States
Arizona Liver Health - GlendaePeoria, Arizona, United States
Adobe Clinical Research LLCTucson, Arizona, United States
Aizona Liver HealthTucson, Arizona, United States
San Fernando Valley Health InstituteCanoga Park, California, United States
Clinnova Research SolutionsGarden Grove, California, United States
Catalina Research InstituteMontclair, California, United States
California Liver InstitutePasadena, California, United States
Inland Empire Liver FoundationRialto, California, United States
Excel Medical Clinical Trials, LLCBoca Raton, Florida, United States
Tampa Bay Medical Research, Inc.Clearwater, Florida, United States
Covenant Metabolic Specialists - Fort MeyersFort Myers, Florida, United States

+ 33 more locations — full list on the registry record.

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

ChandlerPeoriaTucsonCanoga Park

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →